{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:26:42Z","timestamp":1792715202990,"version":"4.5.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"2","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272337"],"award-info":[{"award-number":["81272337"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Women with positive high-risk human papillomavirus (hrHPV) need efficient triage testing to determine colposcopy referrals. Triage strategies of combining p16\/Ki-67 with extended HPV genotyping were evaluated in this study. In total, 899 women attending cervical cancer screening program and 858 women referred to colposcopy from five hospitals were recruited. All the participants were tested by HPV assays and p16\/Ki-67 dual staining. Colposcopy and biopsy were performed on women with any abnormal results. HPV genotypes were divided into four strata (HPV16\/18, HPV31\/33\/58\/52, HPV45\/59\/56\/66, and HPV51\/39\/68\/35) according to their risks for cervical intraepithelial neoplasia grade 3 or worse (CIN3+). The positive rates of four genotype strata among CIN3+ women were 3.47% (HPV51\/39\/68\/35), 7.73% (HPV45\/59\/56\/66), 14.7% (HPV31\/33\/58\/52), and 78.1% (HPV16\/18), respectively (Ptrend &amp;lt; 0.001). The positive rates of p16\/Ki-67 increased with the elevation of HPV risk hierarchical from 65.0% in HPV51\/39\/68\/35-positive women to 88.0% in HPV16\/18-positive women (Ptrend &amp;lt; 0.001). p16\/Ki-67 was an effective method for risk stratification of CIN2+ among HPV31\/33\/58\/52- and HPV45\/59\/56\/66-positive women [HPV31\/33\/58\/52: OR for dual stain+ (ORDS+) of 26.7 (16.8\u201342.4) and OR for dual stain\u2212 (ORDS\u2212) of 3.87(1.89\u20137.91); HPV45\/59\/56\/66: ORDS+ of 10.3(5.05\u201321.0) and ORDS\u2212 of 1.27(0.38\u20134.26)]. The combination of HPV16\/18 genotyping and p16\/Ki-67 triage of HPV31\/33\/58\/52\/45\/59\/56\/66-positive women resulted in a lower referral rate (40.1% vs. 41.3%; P &amp;lt; 0.001) as compared with triage of 12 other HPV-positive women with p16\/Ki-67, although sensitivity and specificity levels for these two strategies were identical. Combining HPV extended genotyping and p16\/Ki-67 can be considered as a promising strategy for cervical cancer screening and triage.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-19-0144","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T15:35:14Z","timestamp":1577115314000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Performance of HPV Genotyping Combined with p16\/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women"],"prefix":"10.1158","volume":"13","author":[{"given":"Ming-Yue","family":"Jiang","sequence":"first","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeni","family":"Wu","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyuan","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."},{"name":"2Office of Cancer Prevention and Treatment, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."},{"name":"3RNA Biology Laboratory, Tumor Virus RNA Biology Section, Center for Cancer Research, NCI, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"4Department of Cancer Epidemiology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Department of Pathology, National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengpeng","family":"Qu","sequence":"additional","affiliation":[{"name":"6Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisong","family":"Sun","sequence":"additional","affiliation":[{"name":"6Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Rong","family":"Xi","sequence":"additional","affiliation":[{"name":"7Department of Gynecology and Obstetrics, The Second Affiliated Hospital, Medical College, Sichuan University, Chengdu, Sichuan, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."},{"name":"8Department of Research, Cancer Registry of Norway, Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangdong","family":"Liao","sequence":"additional","affiliation":[{"name":"7Department of Gynecology and Obstetrics, The Second Affiliated Hospital, Medical College, Sichuan University, Chengdu, Sichuan, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Sun","sequence":"additional","affiliation":[{"name":"9Department of Gynecological Oncology, Shanxi Cancer Hospital, Taiyuan, Shanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"10Department of Epidemiology, Shanxi Cancer Hospital, Taiyuan, Shanxi, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-0871","authenticated-orcid":false,"given":"You-Lin","family":"Qiao","sequence":"additional","affiliation":[{"name":"1Department of Epidemiology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"2022060815434918200_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2022060815434918200_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"2022060815434918200_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/AOG.0000000000000669","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"125","author":"Huh","year":"2015","journal-title":"Obstet Gynecol"},{"key":"2022060815434918200_bib4","doi-asserted-by":"crossref","first-page":"e0163509","DOI":"10.1371\/journal.pone.0163509","article-title":"Optimal management strategies for primary HPV testing for cervical screening: cost-effectiveness evaluation for the National Cervical Screening Program in Australia","volume":"12","author":"Simms","year":"2017","journal-title":"PLoS One"},{"key":"2022060815434918200_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/ijc.30454","article-title":"HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer","volume":"140","author":"Ogilvie","year":"2017","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2022060815434918200_bib7","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2007.07.067","article-title":"Human papillomavirus infection: epidemiology and pathophysiology","volume":"107","author":"Steben","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2022060815434918200_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3322\/caac.21139","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2022060815434918200_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3322\/caac.21261","article-title":"Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening","volume":"65","author":"Smith","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2022060815434918200_bib10","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1001\/jama.285.11.1500","article-title":"Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study","volume":"285","author":"Stoler","year":"2001","journal-title":"JAMA"},{"key":"2022060815434918200_bib11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/ijc.28514","article-title":"Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial","volume":"134","author":"Wright","year":"2014","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib12","first-page":"212","article-title":"Interobserver reproducibility of cytologic p16INK4a\/Ki-67 dual immunostaining in human papillomavirus-positive women","volume":"125","author":"Benevolo","year":"2017","journal-title":"Cancer"},{"key":"2022060815434918200_bib13","doi-asserted-by":"crossref","first-page":"djv257","DOI":"10.1093\/jnci\/djv257","article-title":"p16\/Ki-67 dual stain cytology for detection of cervical precancer in HPV-positive women","volume":"107","author":"Wentzensen","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2022060815434918200_bib14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/modpathol.2016.80","article-title":"p16\/Ki-67 dual-stained cytology for detecting cervical (pre)cancer in a HPV-positive gynecologic outpatient population","volume":"29","author":"Luttmer","year":"2016","journal-title":"Mod Pathol"},{"key":"2022060815434918200_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","article-title":"Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial","volume":"144","author":"Wright","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2022060815434918200_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1309\/AJCP53KMHNRDICBL","article-title":"Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens","volume":"142","author":"Wright","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"2022060815434918200_bib17","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1002\/ijc.30375","article-title":"A cohort study of cervical screening using partial HPV typing and cytology triage","volume":"139","author":"Schiffman","year":"2016","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.02116-14","article-title":"A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results","volume":"53","author":"Schiffman","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2022060815434918200_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ypmed.2016.11.030","article-title":"Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening","volume":"98","author":"Tota","year":"2017","journal-title":"Prev Med"},{"key":"2022060815434918200_bib20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14737159.2016.1217157","article-title":"Management of high-risk HPV-positive women for detection of cervical (pre)cancer","volume":"16","author":"Luttmer","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"2022060815434918200_bib21","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/ijc.27485","article-title":"Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer","volume":"131","author":"Guan","year":"2012","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/ijc.28485","article-title":"p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China","volume":"134","author":"Liao","year":"2014","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib23","doi-asserted-by":"crossref","first-page":"64810","DOI":"10.18632\/oncotarget.11705","article-title":"p16\/Ki-67 co-expression associates high risk human papillomavirus persistence and cervical histopathology: a 3-year cohort study in China","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"2022060815434918200_bib24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2017.11.025","article-title":"Is human papillomavirus genotype important in predicting disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US) cytology?","volume":"148","author":"Kang","year":"2018","journal-title":"Gynecol Oncol"},{"key":"2022060815434918200_bib25","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1055-9965.EPI-13-0846","article-title":"The natural history of cervical cancer in Chinese women: results from an 11-year follow-up study in china using a multistate model","volume":"23","author":"Zhang","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060815434918200_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"2022060815434918200_bib27","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","article-title":"Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study","volume":"12","author":"Castle","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022060815434918200_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/1055-9965.EPI-16-0705","article-title":"Comparison of triage strategies for HPV-positive women: Canadian Cervical Cancer Screening Trial results","volume":"26","author":"Isidean","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060815434918200_bib29","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/modpathol.2017.16","article-title":"Evaluation of p16|[sol]|Ki-67 dual-stained cytology as triage test for high-risk human papillomavirus-positive women","volume":"30","author":"Ebisch","year":"2017","journal-title":"Mod Pathol"},{"key":"2022060815434918200_bib30","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamainternmed.2019.0306","article-title":"Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical cancer screening program","volume":"179","author":"Wentzensen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2022060815434918200_bib31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1158\/1055-9965.EPI-17-0534","article-title":"Defining optimal triage strategies for hrHPV screen-positive Women-An Evaluation of HPV 16\/18 Genotyping, Cytology, and p16\/Ki-67 cytoimmunochemistry","volume":"26","author":"Stanczuk","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060815434918200_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ijc.29353","article-title":"Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women","volume":"137","author":"Bigoni","year":"2015","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ijc.30695","article-title":"Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: a systematic review","volume":"141","author":"Mezei","year":"2017","journal-title":"Int J Cancer"},{"key":"2022060815434918200_bib34","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"121","author":"Massad","year":"2013","journal-title":"Obstet Gynecol"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/13\/2\/163\/2245392\/163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/13\/2\/163\/2245392\/163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T12:17:03Z","timestamp":1654690623000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/13\/2\/163\/47363\/Performance-of-HPV-Genotyping-Combined-with-p16-Ki"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-19-0144","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}